Evidence map›Paper›PMID 33805914›Full record

ArticleSensors (Basel, Switzerland)2021

Step Length Is a Promising Progression Marker in Parkinson's Disease.

Julius Welzel, David Wendtland, Elke Warmerdam, Robbin Romijnders, Morad Elshehabi, Johanna Geritz, Daniela Berg, Clint Hansen, Walter Maetzler

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Julius WelzelDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.
David WendtlandDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.
Elke WarmerdamDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.ORCID 0000-0002-2343-7761
Robbin RomijndersDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.ORCID 0000-0002-2507-0924
Morad ElshehabiDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.
Johanna GeritzDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.
Daniela BergDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.
Clint HansenDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.ORCID 0000-0003-4813-3868
Walter MaetzlerDepartment of Neurology, Kiel University, Arnold-Heller-Straße 3, 24105 Kiel, Germany.ORCID 0000-0002-5945-4694
Christian-Albrechts-Universität zu Kiel · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current research on Parkinson's disease (PD) is increasingly concerned with the identification of objective and specific markers to make reliable statements about the effect of therapy and disease progression. Parameters from inertial measurement units (IMUs) are objective and accurate, and thus an interesting option to be included in the regular assessment of these patients. In this study, 68 patients with PD (PwP) in Hoehn and Yahr (H&Y) stages 1-4 were assessed with two gait tasks-20 m straight walk and circular walk-using IMUs. In an ANCOVA model, we found a significant and large effect of the H&Y scores on step length in both tasks, and only a minor effect on step time. This study provides evidence that from the two potentially most important gait parameters currently accessible with wearable technology under supervised assessment strategies, step length changes substantially over the course of PD, while step time shows surprisingly little change in the progression of PD. These results show the importance of carefully evaluating quantitative gait parameters to make assumptions about disease progression, and the potential of the granular evaluation of symptoms such as gait deficits when monitoring chronic progressive diseases such as PD.

Indexed as

Gait Disorders, NeurologicParkinson DiseaseWearable Electronic DevicesGaitHumansWalkinggaitinertial measurement unitmovement disordersParkinson’s disease

Identifiers

PMID33805914
PMCPMC8037757
OpenAlexW3138938224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.